DocMorris falls in premarket as H1 growth trails Redcare

DocMorris AG

19/08/2025 07:56

** Shares in Swiss drug retailer DocMorris DOCM.S are seen down 4% in premarket indications after the group's H1 sales missed consensus expectations and sales growth fell short of its German competitor Redcare Pharmacy RDC.DE

** The company's H1 group sales missed consensus by 2%, driven by Germany in both prescription and non-prescription sales, Baader Helvea says

** Zuercher Kantonalbank also points to continued weakness in over-the-counter sales

** Baader Helvea says DocMorris' sales growth momentum excluding FX of 10.2% in the first half of 2025 compares unfavourably to Redcare Pharmacy's 27.3% sales growth

** Prescription sales in Germany grew by 40.5% in H1, underperforming Redcare's 160% growth, the broker adds

** DocMorris is seen at the bottom of Switzerland's mid-cap index .SMIM

 (Reporting by Bernadette Hogg)

 ((bernadette.hogg@thomsonreuters.com))